• Gilead Sciences management commentary highlighted third-quarter 2026 sales excluding Veklury of $8.2 billion, up 16%, driven by HIV, Trodelvy and Livdelzi.
• HIV sales rose 18% to $6.2 billion, reflecting higher realized prices, stronger demand and favorable inventory dynamics.
• Trodelvy sales grew 42% on stronger breast cancer demand, while competitive pressures drove an 18% decline in cell therapy sales.
• Non-GAAP diluted earnings reached $2.55 per share, reflecting higher product sales and lower acquired research expenses, partly offset by higher operating expenses.
• Management raised full-year sales guidance excluding Veklury to $30.7 billion–$31 billion, increasing the midpoint by $900 million from August.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief on October 29, 2026, and is solely responsible for the information contained therein.